Marion A. Howard is a business, medical and science professional with a proven track record in strategy design, competitive positioning, market analysis, and due diligence of early and late stage products and technologies. She has strong proficiency in forecasting and valuation using traditional NPV and risk-adjusted NPV analysis, combined with an in depth understanding of molecular and cellular biology and translational medicine. Dr. Howard has also incorporated advanced Real Option analysis to value and guide strategic and operational business decisions.
Prior to founding Cambridge BioStrategies, Dr. Howard helped several start-up companies in the US and Europe to refine their business strategy, raise capital, prepare commercial plans, and pursue licensing and acquisition opportunities. She was also part of the Corporate Development Group at Genzyme General where she reviewed in-licensing and acquisition opportunities and completed technical, strategic and market assessments of specific therapeutic areas. Dr. Howard was trained as an MD/PhD in Germany, the US and the UK; she held various senior academic positions in Translational Medicine before doing her MBA in the UK and the US.